Possis catheter approval
This article was originally published in The Gray Sheet
Executive Summary
Possis gains PMA supplement approval for AngioJet Spiroflex catheter for removal of blood clots from coronary arteries, the firm announces Jan. 30. Possis will launch Spiroflex through its 80-rep sales force into the roughly $150 million domestic coronary thrombectomy market. Spiroflex offers increased trackability and improved crossing in difficult anatomy compared with earlier versions, as well as quick 360-degree thrombus removal, Possis says. The Minneapolis-based firm expects approval of its SpiroflexVG for use in saphenous vein bypass grafts in the heart and larger native coronary vessels this year...
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.